Sector News

Ipsen signs option to buy UCL spin-out Canbex

February 24, 2015
Life sciences
France’s Ipsen has bought an option to acquire the UK’s Canbex Therapeutics, which is working on a treatment for spasticity in people with multiple sclerosis.
 
Canbex is a spin-off of University College London that raised £2.3 million in 2013 from MS Ventures (the corporate venture arm of Merck KGaA), the Wellcome Trust and UCL Business. The therapy in question, called VSN16R, which has been shown in preclinical and Phase I studies to have the potential to provide substantially better patient care than existing systemic anti-spastic treatments, Ipsen says.
 
Ipsen has paid 6 million euros for the option to acquire Canbex at completion of a Phase IIa study. The latter’s present shareholders will be eligible to receive up to an additional 90 million euros, comprising an acquisition payment, plus royalties on VSN16R.
 
Ipsen chief executive Marc de Garidel said Canbex’ lead compound “has demonstrated excellent safety, efficacy and tolerability to date and fits well within our neurology franchise”. He added that “it could be a valuable companion product” to his company’s wrinkles and cervical dystonia treatment Dysport (abobotulinumtoxin A) in the treatment of spasticity.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach